Centre Hospitalier Blois Simone Veil
- Address
- lock Available on a paid plan
Centre Hospitalier Blois Simone Veil - Oncology & Hematology Research Center
Centre Hospitalier Blois Simone Veil is a comprehensive clinical research center with significant expertise in oncology and hematology. The center participates in advanced phase III clinical trials focusing on precision medicine approaches, including circulating tumor DNA (ctDNA) monitoring and personalized treatment strategies for cancer patients.
- Multiple Myeloma: comprehensive research programs evaluating novel biologics including elranatamab, daratumumab, and isatuximab in combination therapies, with focus on minimal residual disease (MRD) adapted strategies
- Breast Cancer: investigating hormone-sensitive breast cancer treatments, including studies on treatment duration optimization, CDK4/6 inhibitors with ribociclib and palbociclib, and gene expression-driven personalized therapy decisions
- Colorectal Cancer: pioneering ctDNA-based decision making for adjuvant treatment, evaluating FOLFOX, FOLFIRI, and bevacizumab regimens in both stage II and stage III disease
- Rare Diseases: participation in studies for Behçet's disease uveitis, warm autoimmune hemolytic anemia (wAIHA), and chronic obstructive pulmonary disease (COPD)
The center demonstrates particular strength in liquid biopsy technologies and biomarker-driven treatment strategies, contributing to major French cooperative group trials including PRODIGE and IFM studies. Their research portfolio emphasizes optimizing treatment duration, reducing unnecessary chemotherapy exposure, and implementing maintenance therapy strategies across multiple cancer types.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 9 therapeutic areas and 15 of 63 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 58 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Unicancer8trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier Blois Simone Veil
lock Showing 1 of 29 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multicentre, double-blind, randomized controlled trial of inhaled amikacin versus placebo in critically ill patients with ventilator-associated tracheobronchitis (AMIVAT) | Centre Hospitalier Regional Universitaire De Tours | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 63 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Dexamethasone | 4 | Unknown | 2019-10-07 | 2025-07-09 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.